1. Microchips Biotech Technology
6th Annual Pharmaceutical Program Symposium
Innovative access: using technology to improve delivery, quality, and use of medicines
March 22, 2017
CONFIDENTIAL • © MICROCHIPS BIOTECH

2. The Microchips Biotech Opportunity
Drug Delivery
Drug Adherence
Strong Partnerships
System Modularity
The world’s most advanced electronic implantable drug delivery system with over 15 years of research, engineering and clinical data behind it
Tackling the $290 billion problem of drug adherence by integrating revolutionary digitally-controlled drug delivery into the healthcare system
Validating partnerships in several important therapeutic areas – TEVA and Bill & Melinda Gates Foundation
Commercially viable platform across multiple applications leveraging our modular system
Investors
Founders
Robert Langer, ScD
Michael Cima, PhD
CONFIDENTIAL • © MICROCHIPS BIOTECH

3. Overview of Device Platform
Microchip-based Implant
Self-contained, battery-powered drug delivery device capable of wireless communication
Stores hundreds of therapeutic drug doses for release over months or years
Implanted subcutaneously in physician’s office (abdomen or other anatomical locations)
200 Reservoirs; ~ 22 x 28 x 8 mm Reservoirs ~ 22 x 40 x 8 mm
CONFIDENTIAL • © MICROCHIPS BIOTECH

4. Overview: How the Technology Works
Drug Storage
Individual doses are stored in micro-reservoir arrays
Reservoirs are hermetically sealed at room temperature
Thin metallic membranes over each reservoir protect drug post-sealing
Drug Release
Drug doses are initiated automatically on schedule or wirelessly on-demand by patient or clinician
Reservoirs are opened via electrothermal activation of membranes
Upon opening, interstitial fluid diffuses in and drug diffuses out
CONFIDENTIAL • © MICROCHIPS BIOTECH

5. Numerous Real-time Solutions for Drug Adherence
Improving convenience for established therapies that require frequent, long-term dosing, or delivery via injection including freedom from injection pain and infection risk
Improving drug effectiveness and outcomes where compliance is critical in both chronic and acute diseases
Automatic dosing for patients with compliance difficulties including the elderly, psychiatric patients and patients with cognitive dysfunction
Developing countries where patients cannot access regular healthcare
Compliance = Improved Outcomes = Improved Healthcare
CONFIDENTIAL • © MICROCHIPS BIOTECH

6. Broad Therapeutic Applicability
Microchips Platform
Orphan Indications
Autoimmune Disorders
CVD
Chronic Diseases
Cognitive Disorders
Women’s Health
The Microchips platform has broad applicability across therapeutic indications including osteoporosis, diabetes and other chronic diseases and women’s contraception.
CONFIDENTIAL • © MICROCHIPS BIOTECH